Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and AUNG NAING.
FUNDA MERIC-BERNSTAM
Connection Strength
8.301
AUNG NAING
  1. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
    View in: PubMed
    Score: 0.247
  2. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. 2024 Feb; 13(3):e6877.
    View in: PubMed
    Score: 0.246
  3. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer. 2024 02 01; 130(3):400-409.
    View in: PubMed
    Score: 0.242
  4. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8).
    View in: PubMed
    Score: 0.238
  5. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel). 2023 Jul 27; 15(15).
    View in: PubMed
    Score: 0.238
  6. Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer. Cancer. 2023 09 01; 129(17):2685-2693.
    View in: PubMed
    Score: 0.234
  7. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
    View in: PubMed
    Score: 0.233
  8. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
    View in: PubMed
    Score: 0.227
  9. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
    View in: PubMed
    Score: 0.223
  10. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel). 2022 Jul 29; 14(15).
    View in: PubMed
    Score: 0.222
  11. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5).
    View in: PubMed
    Score: 0.218
  12. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022 02; 40(1):124-133.
    View in: PubMed
    Score: 0.209
  13. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial. Adv Ther. 2021 08; 38(8):4581-4591.
    View in: PubMed
    Score: 0.206
  14. Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52.
    View in: PubMed
    Score: 0.204
  15. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847.
    View in: PubMed
    Score: 0.202
  16. Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist. 2021 07; 26(7):558-e1098.
    View in: PubMed
    Score: 0.201
  17. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020 12; 8(2).
    View in: PubMed
    Score: 0.198
  18. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402.
    View in: PubMed
    Score: 0.197
  19. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
    View in: PubMed
    Score: 0.188
  20. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
    View in: PubMed
    Score: 0.182
  21. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
    View in: PubMed
    Score: 0.160
  22. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
    View in: PubMed
    Score: 0.160
  23. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93.
    View in: PubMed
    Score: 0.157
  24. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67.
    View in: PubMed
    Score: 0.148
  25. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
    View in: PubMed
    Score: 0.145
  26. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
    View in: PubMed
    Score: 0.144
  27. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
    View in: PubMed
    Score: 0.143
  28. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10.
    View in: PubMed
    Score: 0.139
  29. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
    View in: PubMed
    Score: 0.137
  30. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol. 2015 Oct; 9(8):1501-9.
    View in: PubMed
    Score: 0.136
  31. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
    View in: PubMed
    Score: 0.129
  32. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.058
  33. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37.
    View in: PubMed
    Score: 0.058
  34. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.
    View in: PubMed
    Score: 0.058
  35. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
    View in: PubMed
    Score: 0.057
  36. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
    View in: PubMed
    Score: 0.057
  37. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
    View in: PubMed
    Score: 0.057
  38. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.
    View in: PubMed
    Score: 0.056
  39. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512.
    View in: PubMed
    Score: 0.055
  40. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
    View in: PubMed
    Score: 0.055
  41. Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):461.
    View in: PubMed
    Score: 0.054
  42. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):463.
    View in: PubMed
    Score: 0.054
  43. Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study. J Immunother Precis Oncol. 2022 Feb; 5(1):10-12.
    View in: PubMed
    Score: 0.054
  44. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59.
    View in: PubMed
    Score: 0.053
  45. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299.
    View in: PubMed
    Score: 0.052
  46. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.
    View in: PubMed
    Score: 0.052
  47. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049.
    View in: PubMed
    Score: 0.051
  48. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Invest New Drugs. 2021 10; 39(5):1357-1365.
    View in: PubMed
    Score: 0.051
  49. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.
    View in: PubMed
    Score: 0.051
  50. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402.
    View in: PubMed
    Score: 0.050
  51. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073.
    View in: PubMed
    Score: 0.049
  52. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.
    View in: PubMed
    Score: 0.049
  53. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.048
  54. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7.
    View in: PubMed
    Score: 0.047
  55. Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol. 2019 12; 49(12):2245-2251.
    View in: PubMed
    Score: 0.046
  56. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158.
    View in: PubMed
    Score: 0.045
  57. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.043
  58. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270.
    View in: PubMed
    Score: 0.042
  59. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243.
    View in: PubMed
    Score: 0.042
  60. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424.
    View in: PubMed
    Score: 0.041
  61. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.
    View in: PubMed
    Score: 0.041
  62. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769.
    View in: PubMed
    Score: 0.041
  63. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
    View in: PubMed
    Score: 0.040
  64. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
    View in: PubMed
    Score: 0.040
  65. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017.
    View in: PubMed
    Score: 0.040
  66. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
    View in: PubMed
    Score: 0.039
  67. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
    View in: PubMed
    Score: 0.039
  68. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).
    View in: PubMed
    Score: 0.038
  69. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
    View in: PubMed
    Score: 0.038
  70. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
    View in: PubMed
    Score: 0.037
  71. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20.
    View in: PubMed
    Score: 0.037
  72. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
    View in: PubMed
    Score: 0.037
  73. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.
    View in: PubMed
    Score: 0.037
  74. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
    View in: PubMed
    Score: 0.037
  75. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
    View in: PubMed
    Score: 0.036
  76. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94.
    View in: PubMed
    Score: 0.035
  77. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581.
    View in: PubMed
    Score: 0.034
  78. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
    View in: PubMed
    Score: 0.034
  79. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
    View in: PubMed
    Score: 0.032
  80. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.032
  81. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388.
    View in: PubMed
    Score: 0.031
  82. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13.
    View in: PubMed
    Score: 0.030
  83. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
    View in: PubMed
    Score: 0.030
  84. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.